VistaGen Therapeutics, Inc., a biotechnology company, focuses on applying proprietary human pluripotent stem cell technology for technology for drug rescue, predictive toxicology, and drug metabolism screening. The company has developed CardioSafe 3D, a novel three-dimensional in vitro bioassay system for predicting in vivo cardiac effects, both toxic and non-toxic, of small molecule drug candidates before they are tested in animals or humans. It is also developing and validating LiverSafe 3D, a novel three-dimensional in vitro bioassay system for assessing liver toxicity and drug metabolism issues. In addition, the company product candidates include AV-101, an orally available small molecule that has completed Phase 1 development for the treatment of neurological disease and disorders market, including neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
March 15, 2018
RegMed Investors’ (RMi) closing bell; swimming against the tide
March 14, 2018
RegMed Investors’ (RMi) closing bell; what started up, ended with another slip and fall
March 13, 2018
RegMed Investors’ (RMi) closing bell; get used to the game of musical pricing chairs
March 12, 2018
RegMed Investors’ (RMi) closing bell; what the market gives, it also takes away
March 10, 2018
Regenerative Medicine Earnings Scorecard - Q4 and FY17 - to date
March 9, 2018
RegMed Investors’ (RMi) closing bell; what is the accurate perception of sector realities
March 8, 2018
RegMed Investors’ (RMi) closing bell; the trend is not always your friend
March 7, 2018
RegMed Investors’ (RMi) pre-open: it’s just another test of lows and resistance
March 6, 2018
RegMed Investors’ (RMi) closing bell; flickering
March 4, 2018
RegMed Investors’ (RMi) wrapping-up January and February while determining March’s strength …
35 companies, 1 interpreter!
Insight, foresight and recommendation
VistaGen (VTGN) – Started 2018 at $1.16, February saw $1.16 and March opened at $1.18 jumping to $1.47 on 3/6. Financing is always an issue yet it ended 2017 with $13 M in cash ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors